EUCTR2012-001781-15-ES进行中（未招募）不适用
Initial protocol setting for the treatment of choroidal neovascularization associated to myopia magna with intravitreal bevacizumab: 3 vs 1 (BENEMCOR.es study) - BENEMCOR.es
IOBA, Universidad de Valladolid0 个研究点开始时间: 2012年5月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1-Myopic patients over 18 years with active subfoveal choroidal neovascularisation associated to yuxtafoveolar myopia confirmed by AGF and OCT.
- •2-Patients with loss of visual acuity less than 6 months lenght caused by the neovascular lesion at the discretion of the researcher.
- •3-Lesions in which the presence of atrophic or fibrotic component does not prevent vision improvement .
- •4-4-Patients with active subfoveal and yuxtafoveolar choroidal neovascularization associated with myopia magna previously treated with photodynamic therapy.
- •5-Informed written consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1-Previous surgery vitrectomy.
- •2-tractional maculopathy and/or idiopathic epiretinal membrane diagnosed by OCT.
- •3-media opacity that does not allow to adequately assess the fundus of the eye.
- •4-Lack of integrity of the posterior lens capsule in pseudophakia.
研究者
相似试验
尚未招募
不适用
Work Injury Screening and Early intervention (WISE) StudyWork related soft tissue injuriesMusculoskeletal - Other muscular and skeletal disordersACTRN12613000847718Sydney Medical School (Northern) - University of Sydney220
尚未招募
1 期
Clinical study protocol for the treatment of moderate to severe persistent allergic rhinitis with lung-deficiency-related cold type by fire acupuncture at the Inner Yingxiang(Ex-HN09) pointAllergic RhinitisITMCTR2200006073Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
进行中（未招募）
不适用
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1Level: LLYClassification code 10062427EUCTR2004-001093-11-SEPfizer Ltd
进行中（未招募）
不适用
A Treatment Protocol for Patients Continuing from Prior SU0011248 ProtocolGastrointestinal stromal tumorEUCTR2004-001093-11-ESPfizer SA
进行中（未招募）
1 期
A Treatment Protocol for Patients Continuing from a Prior SU011248 ProtocolThis is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248 treatment. Included in this protocol will be patients assigned to placebo in a previous study who did not qualify for crossover within the original protocol due to declining health status (eg, performance status lower than crossover eligibility criterionMedDRA version: 7.1 Level: LLY Classification code 10062427EUCTR2004-001093-11-GBPfizer Global Research and Development